Yazan Abou-Ismail/ LinkedIn
Nov 10, 2026, 14:55
Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
Yazan Abou-Ismail, Associate Professor of Hematology at the University of Utah, shared a post on LinkedIn:
“An exciting breakthrough in thrombosis prevention!
Factor 11a inhibitors are finally here!
We now have the first ever FDA approved Factor 11a inhibitor.
The FDA just approved asundexian for secondary prevention of non Afib stroke.
Factor 11a inhibition is a brand new mechanism of anticoagulation and major milestone in the #coagulation world.
In the phase III Oceanic Stroke trial, asundexian reduced the relative risk of ischemic stroke by 26 percent when added to antiplatelet therapy, without a statistically significant increase in overall major bleeding.”
Stay updated with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery
-
Nov 10, 2026, 14:37Salih Ehsan: Common Causes of Microcytic Anemia